One important consideration from existing GLP-1 receptor agonist research is the likelihood of weight regain after discontinuation
Red meats (i.e., beef, pork, & mutton) contain much more L-carnitine than dairy products, eggs, poultry or seafood and far more than plant foods

Immediate emergency care (call 911) is necessary if you experience: Signs of severe allergic reaction (anaphylaxis): difficulty breathing, severe swelling of face or throat, rapid heartbeat, severe dizziness, or widespread rash Symptoms suggesting pancreatitis: severe, persistent abdominal pain that may radiate to the back, often accompanied by nausea and vomiting Signs of thyroid tumor: new lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath Contact your healthcare provider within 24 hours for: Persistent injection site reactions lasting more than a few days, including significant redness, swelling, hardness, or pain Signs of infection at the injection site: increasing warmth, red streaking, pus, or fever Severe or persistent gastrointestinal symptoms (nausea, vomiting, diarrhea) that interfere with eating or hydration Symptoms of hypoglycemia (if taking semaglutide with insulin or sulfonylureas): excessive sweating, shakiness, confusion, rapid heartbeat, or extreme hunger Changes in vision or eye pain, especially if you have a history of diabetic retinopathy Symptoms of gallbladder problems: pain in the upper right abdomen, fever, yellowing of skin or eyes, clay-colored stools Unexplained rapid heartbeat or palpitations Signs of kidney problems: significant changes in urination, swelling in legs or feet, unusual fatigue Routine follow-up is appropriate for: Questions about proper injection technique or site rotation Mild, transient injection site reactions that resolve within a day General questions about medication storage or handling Difficulty with pen operation or concerns about dose delivery Your healthcare provider should monitor your response to semaglutide through regular follow-up appointments, typically including assessment of glycemic control (for diabetes treatment), weight changes, and potential adverse effects

The number of Americans taking these medications has roughly doubled in just two years from around five million in 2023 to roughly 10 million today